AI in Drug Discovery Monitor
Tracking how AI is compressing drug development timelines from 12 years to under 5, and cutting costs by 60%. Data from Nature Medicine, The Lancet Digital Health, PharmaIntelligence, ClinicalTrials.gov, AlphaFold DB.
The AI Pharma Revolution
AI-first drug discovery companies have raised over $4.2 billion in 2025. There are now 24 AI-discovered drug candidates in clinical trials, with 3 in Phase III — up from zero in 2020.
AlphaFold 3 can predict the structure of DNA, RNA, and small molecules alongside proteins, enabling multi-modal drug design. This has reduced target identification time from 4 years to 6 months.
Key Players & Funding
Isomorphic Labs (DeepMind spinout), Recursion Pharmaceuticals, Insilico Medicine, and Exscientia lead the field. Big pharma partnerships with AI companies totaled $12B in deal value in 2025.
Clinical Trial Optimization
AI-optimized clinical trial design has reduced patient recruitment time by 45% and improved trial success rates from 12% to 21% for Phase II candidates.